Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro,Masatoshi Kudo,Joseph P. Erinjeri,Shukui Qin,Zhenggang Ren,Stephen L. Chan,Yasuaki Arai,Jeong Heo,Anh Thi Lan,José J. Escobar,Yamil Alonso Lopez Chuken,Jung‐Hwan Yoon,Won Young Tak,В. В. Бредер,Tanita Suttichaimongkol,Mohamed Bouattour,Shi-Ming Lin,Jean‐Marie Péron,Quang T. Nguyen,Lünan Yan